Identification

Name
Trazodone
Accession Number
DB00656  (APRD00533)
Type
Small Molecule
Groups
Approved, Investigational
Description

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Structure
Thumb
Synonyms
  • 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
  • Trazodona
  • Trazodone
  • Trazodonum
External IDs
J10.767K
Product Ingredients
IngredientUNIICASInChI Key
Trazodone Hydrochloride6E8ZO8LRNM25332-39-2OHHDIOKRWWOXMT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desyrel Dividose Tab 300mgTablet300 mgOralBristol Labs Division Of Bristol Myers Squibb1989-12-311999-08-09Canada
Desyrel Dividose Tablet 150 mgTablet150 mgOralBristol Myers Squibb1988-12-312010-01-05Canada
Desyrel Tab 100mgTablet100 mgOralBristol Myers Squibb1983-12-312010-09-07Canada
Desyrel Tab 50mgTablet50 mgOralBristol Myers Squibb1983-12-312010-05-14Canada
OleptroTablet, extended release150 mg/1OralAngelini Pharma Inc.2010-02-022016-03-29Us
OleptroTablet, extended release300 mgOralAngelini Pharma Inc.2011-03-09Not applicableCanada
OleptroTablet, extended release300 mg/1OralAngelini Pharma Inc.2010-02-022016-03-29Us
OleptroTablet, extended release150 mgOralAngelini Pharma Inc.2011-03-09Not applicableCanada
PMS Trazodone HCl Tab 100mgTablet100 mgOralPharmascience Inc1993-12-31Not applicableCanada
PMS Trazodone HCl Tab 50mgTablet50 mgOralPharmascience Inc1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trazodone D Tablets 150mgTablet150 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-trazodone Tablets 100mgTablet100 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-trazodone Tablets 50mgTablet50 mgOralApotex Corporation1995-12-31Not applicableCanada
Dom-trazodone Tablets - 50mgTablet50 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Dom-trazodone Tablets-100mgTablet100 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Mar-trazodoneTablet150 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodoneTablet100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodoneTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-trazodoneTablet150 mgOralMylan Pharmaceuticals1997-11-282016-06-28Canada
Mylan-trazodoneTablet100 mgOralMylan Pharmaceuticals1997-09-052016-06-28Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TrazamineTrazodone Hydrochloride + CholineKitPhysician Therapeutics Llc2011-02-032016-10-13Us
International/Other Brands
Beneficat / Deprax / Desirel / Desyrel (Bristol-Myers Squibb) / Desyrel Dividose (Bristol-Myers Squibb) / Mesyrel / Molipaxin / Thombran / Trialodine / Trittico
Categories
UNII
YBK48BXK30
CAS number
19794-93-5
Weight
Average: 371.864
Monoisotopic: 371.151288058
Chemical Formula
C19H22ClN5O
InChI Key
PHLBKPHSAVXXEF-UHFFFAOYSA-N
InChI
InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
IUPAC Name
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one
SMILES
ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1

Pharmacology

Indication

For the treatment of depression.

Associated Conditions
Pharmacodynamics

Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.

Mechanism of action

Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
A5-hydroxytryptamine receptor 2C
agonist
Human
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 1A
partial agonist
Human
UHistamine H1 receptor
antagonist
Human
NAlpha-1A adrenergic receptor
antagonist
Human
NAlpha-2A adrenergic receptor
antagonist
Human
Absorption

Rapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption.

Volume of distribution
Not Available
Protein binding

89-95% bound to plasma proteins in vitro

Metabolism

Undergoes extensive hepatic metabolism via hydroxylation, N-dealkylation, N-oxidation and splitting of the pyridine ring. Cytochrome P450 (CYP) 3A4 catalyzes the formation of the major active metabolite, m-chlorophenylpiperazine (m-CPP). Metabolites may be further conjugated to glucuonic acid or glutathione. CYP2D6 is responsible for 4'-hydroxylation of m-CPP and the formation of at least one glutathione conjugates of m-CPP, a quinone imine-sulhydryl adduct. Oxotriazolopyridinpropionic acid, an inactive metabolite, and its conjugates account for about 20% of the total excreted oral dose. Less than 1% of the oral dose is excreted unchanged. Approximately 70-75% of the dose is eliminated in urine with the remainder being excreted in feces via biliary elimination.

Route of elimination
Not Available
Half life

Undergoes biphasic elimination with an initial phase t1/2 α of 3-6 hours and a terminal phase t1/2 β of 5-9 hours.

Clearance
Not Available
Toxicity

LD50=96mg/kg (i.v. in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Trazodone.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Trazodone.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Trazodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Trazodone.Experimental, Illicit
4-MethoxyamphetamineTrazodone may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Trazodone.Experimental
AbirateroneThe serum concentration of Trazodone can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
AcepromazineTrazodone may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Trazodone can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Trazodone is combined with Adipiplon.Investigational
AdrafinilTrazodone may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Trazodone.Approved
AgmatineTrazodone may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Trazodone is combined with Agomelatine.Approved, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Trazodone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trazodone.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Trazodone.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Trazodone.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Almotriptan.Approved, Investigational
AlosetronAlosetron may increase the serotonergic activities of Trazodone.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Trazodone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Withdrawn
AmibegronTrazodone may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe metabolism of Trazodone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Amisulpride.Approved, Investigational
AmitrazTrazodone may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineTrazodone may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Trazodone is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trazodone.Approved, Illicit
AmoxapineTrazodone may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trazodone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the serotonergic activities of Trazodone.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Trazodone is combined with Amrinone.Approved
AnagrelideTrazodone may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineTrazodone may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Trazodone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineTrazodone may decrease the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineTrazodone may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Trazodone can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Aranidipine.Approved, Investigational
ArbutamineTrazodone may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTrazodone may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleTrazodone may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Trazodone.Investigational
Arsenic trioxideTrazodone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTrazodone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Articaine.Approved
AsenapineTrazodone may increase the antihypertensive activities of Asenapine.Approved
AtazanavirThe serum concentration of Trazodone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Trazodone.Approved
AtomoxetineThe metabolism of Trazodone can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Trazodone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Azaperone.Investigational, Vet Approved
AzelastineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Trazodone is combined with Azimilide.Investigational
AzithromycinTrazodone may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trazodone.Approved
BambuterolTrazodone may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Barnidipine.Approved
BedaquilineTrazodone may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Trazodone is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Trazodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Trazodone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Benzocaine.Approved, Investigational
BenzphetamineTrazodone may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trazodone is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineTrazodone may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Trazodone is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Trazodone.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
BevantololTrazodone may increase the antihypertensive activities of Bevantolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Trazodone is combined with Bifeprunox.Investigational
BioallethrinThe risk or severity of hypotension can be increased when Trazodone is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Trazodone.Approved
BitolterolTrazodone may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone.Investigational
BoceprevirThe serum concentration of Trazodone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Trazodone.Approved
BortezomibThe metabolism of Trazodone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Trazodone can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.Approved, Investigational
BrexpiprazoleTrazodone may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Trazodone.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trazodone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Trazodone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Trazodone.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Trazodone.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Trazodone.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Trazodone.Approved
BuprenorphineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Trazodone can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Trazodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Trazodone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trazodone is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Trazodone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trazodone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cabergoline.Approved
CanertinibThe risk or severity of adverse effects can be increased when Trazodone is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Trazodone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Trazodone.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Trazodone is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone.Approved
CaroverineThe risk or severity of hypotension can be increased when Trazodone is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the serotonergic activities of Trazodone.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Trazodone.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Trazodone.Approved, Investigational
CelecoxibThe metabolism of Trazodone can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
CeritinibThe serum concentration of Trazodone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trazodone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Trazodone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Trazodone can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Trazodone.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Trazodone.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Trazodone.Experimental
ChlorpromazineTrazodone may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trazodone.Approved
CholecalciferolThe metabolism of Trazodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Trazodone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Trazodone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Trazodone is combined with Cinnarizine.Approved, Investigational
CiprofloxacinTrazodone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineTrazodone may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideTrazodone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the serotonergic activities of Trazodone.Approved
ClarithromycinThe metabolism of Trazodone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trazodone can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolTrazodone may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Trazodone.Approved
ClobazamThe metabolism of Trazodone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Trazodone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trazodone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Trazodone is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Trazodone is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Trazodone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTrazodone may increase the antihypertensive activities of Clozapine.Approved
CobicistatThe serum concentration of Trazodone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Trazodone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trazodone.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Trazodone.Approved, Investigational
CrizotinibThe metabolism of Trazodone can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Trazodone can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyamemazine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Trazodone is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Trazodone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Trazodone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trazodone.Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.Approved
DabrafenibThe serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Trazodone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.Investigational
DarifenacinThe metabolism of Trazodone can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Trazodone is combined with Darodipine.Experimental
DarunavirThe serum concentration of Trazodone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Trazodone can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Trazodone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trazodone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trazodone.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Trazodone.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.Approved, Vet Approved
DextroamphetamineTrazodone may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trazodone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trazodone.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Trazodone is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Trazodone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Trazodone.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trazodone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Trazodone can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trazodone.Approved
DiphenhydramineThe metabolism of Trazodone can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trazodone.Approved, Illicit
DipivefrinTrazodone may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Trazodone.Approved
DisopyramideTrazodone may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dixyrazine.Experimental
DL-MethylephedrineTrazodone may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineTrazodone may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideTrazodone may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Trazodone.Approved, Investigational
DomperidoneTrazodone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineTrazodone may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Trazodone is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Trazodone can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Trazodone is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Trazodone.Approved
DoxepinTrazodone may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineTrazodone may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.Approved, Investigational
DoxycyclineThe metabolism of Trazodone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trazodone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Illicit
DronedaroneTrazodone may increase the antihypertensive activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Drotebanol.Experimental, Illicit
DroxidopaTrazodone may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Trazodone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Trazodone.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Eletriptan.Approved, Investigational
EliglustatTrazodone may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trazodone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trazodone.Approved, Investigational
EnzalutamideThe serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
EperisoneThe risk or severity of hypotension can be increased when Trazodone is combined with Eperisone.Approved, Investigational
EphedraTrazodone may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineTrazodone may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTrazodone may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTrazodone may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergotamine.Approved
ErythromycinThe metabolism of Trazodone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
EscitalopramTrazodone may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Trazodone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trazodone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.Approved, Investigational
EtafedrineTrazodone may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trazodone.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trazodone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etifoxine.Investigational, Withdrawn
EtilefrineTrazodone may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Trazodone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Trazodone.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Trazodone.Approved
FelodipineThe risk or severity of hypotension can be increased when Trazodone is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Trazodone is combined with Fendiline.Withdrawn
FenoterolTrazodone may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Trazodone.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Trazodone is combined with Fish oil.Approved, Nutraceutical
FlecainideTrazodone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trazodone.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Trazodone can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Trazodone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Trazodone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trazodone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trazodone.Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Trazodone.Approved, Investigational
FormoterolTrazodone may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Trazodone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trazodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Trazodone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Trazodone is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Trazodone.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Trazodone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Trazodone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Trazodone.Approved, Investigational
Gadobenic acidTrazodone may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Trazodone is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trazodone.Approved, Illicit, Investigational
GemifloxacinTrazodone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Trazodone.Experimental
GepironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Trazodone is combined with Glutethimide.Approved, Illicit
GoserelinTrazodone may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronGranisetron may increase the serotonergic activities of Trazodone.Approved, Investigational
GuanabenzTrazodone may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Trazodone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Trazodone is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Trazodone.Experimental
HeroinThe risk or severity of adverse effects can be increased when Trazodone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Hexobarbital.Approved
HexoprenalineTrazodone may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTrazodone may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trazodone.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Trazodone.Experimental
HydrocodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Trazodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
IbutilideTrazodone may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Trazodone can be decreased when combined with Idelalisib.Approved
IloperidoneTrazodone may increase the antihypertensive activities of Iloperidone.Approved
ImatinibThe metabolism of Trazodone can be decreased when combined with Imatinib.Approved
ImipramineTrazodone may increase the antihypertensive activities of Imipramine.Approved
IndacaterolTrazodone may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineIndalpine may increase the serotonergic activities of Trazodone.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Trazodone.Withdrawn
IndinavirThe serum concentration of Trazodone can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Trazodone is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Trazodone.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Trazodone.Approved
IproclozideIproclozide may increase the serotonergic activities of Trazodone.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Trazodone.Withdrawn
IsavuconazoleThe serum concentration of Trazodone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Trazodone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Trazodone can be increased when used in combination with Isocarboxazid.Approved
IsoetarineTrazodone may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trazodone.Approved, Vet Approved
IsomethepteneTrazodone may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Trazodone can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineTrazodone may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineTrazodone may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Trazodone can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Trazodone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trazodone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trazodone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Trazodone can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Trazodone.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the antihypertensive activities of Trazodone.Approved
LacidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Trazodone is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Trazodone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Trazodone.Approved
LenvatinibTrazodone may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Trazodone is combined with Lercanidipine.Approved, Investigational
LeuprolideTrazodone may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trazodone.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Trazodone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trazodone.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Trazodone.Approved
LevofloxacinTrazodone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Trazodone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trazodone.Approved
LevosalbutamolTrazodone may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Trazodone is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Trazodone.Approved
LinezolidLinezolid may increase the serotonergic activities of Trazodone.Approved, Investigational
LisdexamfetamineTrazodone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Trazodone can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Trazodone is combined with Loperamide.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Trazodone.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Trazodone.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Trazodone can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Trazodone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.Approved
LuliconazoleThe serum concentration of Trazodone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Trazodone can be increased when combined with Lumacaftor.Approved
LumefantrineTrazodone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Trazodone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Trazodone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Trazodone.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Trazodone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Trazodone.Approved
MedazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Trazodone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Trazodone is combined with Menthol.Approved
MephedroneMephedrone may decrease the sedative activities of Trazodone.Investigational
MephentermineTrazodone may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Trazodone is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.Approved, Investigational
MetaraminolTrazodone may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trazodone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTrazodone may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trazodone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.Approved
MethotrimeprazineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineTrazodone may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineTrazodone may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trazodone.Approved
MethyldopaTrazodone may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Trazodone is combined with Methylecgonine.Experimental
Methylene blueTrazodone may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
MetyrosineTrazodone may increase the sedative activities of Metyrosine.Approved
MibefradilThe risk or severity of hypotension can be increased when Trazodone is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trazodone.Approved, Illicit
MidodrineTrazodone may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Trazodone.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Trazodone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Trazodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the serotonergic activities of Trazodone.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Trazodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
MirabegronThe metabolism of Trazodone can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Trazodone.Investigational
MirtazapineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Trazodone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Trazodone.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Trazodone.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Trazodone.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trazodone.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Mosapramine.Experimental
MoxifloxacinTrazodone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineTrazodone may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Trazodone.Approved
NaftopidilThe risk or severity of hypotension can be increased when Trazodone is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trazodone.Approved
NaphazolineTrazodone may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Naratriptan.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
NefazodoneTrazodone may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Trazodone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trazodone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Trazodone can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Trazodone.Withdrawn
NicardipineTrazodone may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Trazodone.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Trazodone is combined with Nifedipine.Approved
NiguldipineTrazodone may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibTrazodone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Trazodone is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Trazodone is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Trazodone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Trazodone is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Trazodone is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.Approved
NitrendipineThe risk or severity of hypotension can be increased when Trazodone is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trazodone.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Nordazepam.Approved
NorepinephrineTrazodone may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTrazodone may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Normethadone.Approved, Illicit
NortriptylineTrazodone may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinTrazodone may decrease the vasoconstricting activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Trazodone.Withdrawn
OctopamineTrazodone may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinTrazodone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineTrazodone may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Trazodone can be decreased when combined with Olaparib.Approved
OlodaterolTrazodone may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trazodone.Approved
OndansetronOndansetron may increase the serotonergic activities of Trazodone.Approved
OpiumThe risk or severity of adverse effects can be increased when Trazodone is combined with Opium.Approved, Illicit
OrciprenalineTrazodone may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Trazodone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Trazodone is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Trazodone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trazodone.Approved, Illicit, Investigational
OxyfedrineTrazodone may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTrazodone may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trazodone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneTrazodone may increase the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Trazodone.Approved, Investigational
PanobinostatThe serum concentration of Trazodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeTrazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Trazodone.Approved
ParoxetineThe metabolism of Trazodone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibTrazodone may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Trazodone is combined with Penfluridol.Experimental
PentamidineTrazodone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.Approved, Vet Approved
PentobarbitalThe metabolism of Trazodone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trazodone.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Trazodone.Approved, Investigational
PerflutrenTrazodone may increase the QTc-prolonging activities of Perflutren.Approved
PergolideTrazodone may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.Approved
PethidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenazocine.Experimental
PhendimetrazineTrazodone may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Trazodone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the serotonergic activities of Trazodone.Withdrawn
PhenobarbitalThe metabolism of Trazodone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Trazodone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Trazodone.Withdrawn
PhenterminePhentermine may decrease the sedative activities of Trazodone.Approved, Illicit
PhentolamineTrazodone may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineTrazodone may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTrazodone may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Trazodone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideTrazodone may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Trazodone is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipotiazine.Approved, Investigational
PirbuterolTrazodone may decrease the vasoconstricting activities of Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Trazodone.Approved
PitolisantThe serum concentration of Trazodone can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Trazodone.Withdrawn
PizotifenTrazodone may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Trazodone.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trazodone.Approved
PosaconazoleThe metabolism of Trazodone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Trazodone.Approved
PramipexoleTrazodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Trazodone.Approved
PregabalinThe therapeutic efficacy of Trazodone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolTrazodone may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Trazodone is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Prilocaine.Approved
PrimaquineTrazodone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Trazodone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideTrazodone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the serotonergic activities of Trazodone.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Trazodone.Approved, Investigational
ProcaterolTrazodone may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.Approved, Vet Approved
PromazinePromazine may increase the antihypertensive activities of Trazodone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Trazodone.Approved
PropanididThe risk or severity of adverse effects can be increased when Trazodone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Proparacaine.Approved, Vet Approved
PropericiazineTrazodone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineTrazodone may increase the antihypertensive activities of Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Trazodone.Vet Approved
PropiverineTrazodone may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trazodone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Trazodone is combined with Prothipendyl.Investigational
ProtokylolTrazodone may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Trazodone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Trazodone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Trazodone is combined with PSD502.Investigational
PseudoephedrineTrazodone may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trazodone.Approved, Illicit
QuetiapineTrazodone may increase the antihypertensive activities of Quetiapine.Approved
QuinidineTrazodone may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineTrazodone may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Quinisocaine.Experimental
RacepinephrineTrazodone may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Raclopride.Investigational
RactopamineTrazodone may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone.Approved, Investigational
RanolazineThe metabolism of Trazodone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Trazodone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trazodone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.Approved, Withdrawn
ReproterolTrazodone may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trazodone.Approved, Investigational
RifabutinThe metabolism of Trazodone can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Trazodone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trazodone can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineTrazodone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolTrazodone may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneTrazodone may increase the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Ritanserin.Investigational
RitobegronTrazodone may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTrazodone may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Trazodone can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Rizatriptan.Approved
RolapitantThe metabolism of Trazodone can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Romifidine.Vet Approved
RopiniroleTrazodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.Approved
RotigotineTrazodone may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Trazodone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone.Approved
SafrazineSafrazine may increase the serotonergic activities of Trazodone.Withdrawn
SalbutamolTrazodone may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTrazodone may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
SarilumabThe therapeutic efficacy of Trazodone can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Trazodone.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Trazodone is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Trazodone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trazodone.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Trazodone.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Trazodone.Approved
SiltuximabThe serum concentration of Trazodone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Trazodone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Trazodone.Approved
SolabegronTrazodone may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolTrazodone may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Trazodone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Trazodone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trazodone.Approved, Investigational
SulfisoxazoleThe metabolism of Trazodone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Sumatriptan.Approved, Investigational
SuvorexantTrazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineTrazodone may decrease the vasoconstricting activities of Synephrine.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trazodone.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Trazodone.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Trazodone.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Trazodone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Trazodone.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trazodone.Approved
TelaprevirThe serum concentration of Trazodone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTrazodone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Trazodone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Trazodone.Approved
TerbinafineThe metabolism of Trazodone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Trazodone.Approved
TerodilineThe risk or severity of hypotension can be increased when Trazodone is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Trazodone.Experimental
TetrabenazineTrazodone may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrodotoxin.Investigational
TetryzolineTrazodone may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideTrazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Trazodone.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Trazodone.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiopropazate.Experimental
ThioproperazineTrazodone may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Trazodone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trazodone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Trazodone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Trazodone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Trazodone.Approved
TipranavirThe serum concentration of Trazodone can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trazodone.Approved, Investigational
TocilizumabThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the antihypertensive activities of Trazodone.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trazodone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Trazodone is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the serotonergic activities of Trazodone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone.Approved
ToremifeneTrazodone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Trazodone is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the serotonergic activities of Trazodone.Approved, Investigational
TretoquinolTrazodone may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trazodone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Trazodone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trazodone is combined with Trichloroethylene.Approved
TrifluoperazineTrazodone may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trazodone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Trazodone.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Trazodone is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Trazodone is combined with Trimethadione.Approved
TrimipramineTrazodone may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trazodone.Approved
TropisetronTropisetron may increase the serotonergic activities of Trazodone.Approved, Investigational
TulobuterolTrazodone may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Trazodone.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Trazodone.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trazodone.Approved, Investigational
VandetanibTrazodone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Trazodone.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trazodone.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Trazodone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Veralipride.Experimental
VerapamilTrazodone may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Trazodone.Approved
VilanterolTrazodone may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vilazodone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Trazodone is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Trazodone is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Trazodone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.Approved, Investigational
WarfarinTrazodone may decrease the anticoagulant activities of Warfarin.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Trazodone is combined with WIN 55212-2.Experimental
XamoterolTrazodone may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Trazodone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Xylazine.Vet Approved
XylometazolineTrazodone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe therapeutic efficacy of Trazodone can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Trazodone.Approved
ZimelidineZimelidine may increase the serotonergic activities of Trazodone.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Trazodone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Zolmitriptan.Approved, Investigational
ZolpidemTrazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trazodone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trazodone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trazodone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolTrazodone may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Food decreases the rate and extent of absorption.

References

General References
  1. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657]
  2. Jauch R, Kopitar Z, Prox A, Zimmer A: [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung. 1976;26(11):2084-9. [PubMed:1037253]
  3. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194]
  4. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881]
  5. Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y: Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. [PubMed:7673654]
  6. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):249-60. [PubMed:11817501]
  7. Fink HA, MacDonald R, Rutks IR, Wilt TJ: Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003 Sep;92(4):441-6. [PubMed:12930437]
External Links
Human Metabolome Database
HMDB0014794
KEGG Compound
C07156
PubChem Compound
5533
PubChem Substance
46506648
ChemSpider
5332
BindingDB
50073444
ChEBI
9654
ChEMBL
CHEMBL621
Therapeutic Targets Database
DAP000104
PharmGKB
PA451744
IUPHAR
213
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Trazodone
ATC Codes
N06AX05 — Trazodone
AHFS Codes
  • 28:16.04.24 — Serotonin Modulators
FDA label
Download (151 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0SuspendedBasic ScienceSleep Apnea, Obstructive; Post-Traumatic Stress Disorders1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBioavailability / Healthy Volunteers / Pharmacokinetics1
1CompletedTreatmentHealthy Volunteers3
1Not Yet RecruitingTreatmentDepression1
1RecruitingTreatmentSleep Apnea, Obstructive1
1Unknown StatusTreatmentHealthy Volunteers1
2CompletedTreatmentAlcoholism1
2RecruitingBasic ScienceSleep Disordered Breathing (SDB) / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentPainful Diabetic Neuropathy1
2, 3CompletedTreatmentDepression1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAlzheimer's Disease (AD) / Sleep / Sleep disorders and disturbances / Sleeplessness1
3CompletedTreatmentMajor Depressive Disorder (MDD)2
3CompletedTreatmentOpiate Addiction / Poor Quality Sleep1
3CompletedTreatmentSleep Disorder1
3Not Yet RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Sleeplessness1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentInsomnia Comorbid to Psychiatric Disorder / Primary Insomnia1
4CompletedTreatmentFibromyalgia1
4CompletedTreatmentSchizophrenic Disorders1
4Not Yet RecruitingTreatmentPain, Chronic / Sleep Bruxism / Sleep Disorder / TMD / TMJ Pain1
4RecruitingOtherSleep Apnea Syndrome / Spinal Cord Injuries (SCI)1
4TerminatedTreatmentAcute Agitation / Delirium1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMental Health Disorder / Sleeplessness / Substance Use Disorder (SUD)1
Not AvailableActive Not RecruitingTreatmentSleeplessness1
Not AvailableCompletedBasic ScienceSleep Apnea, Obstructive1
Not AvailableCompletedTreatmentSexual Dysfunctions1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depression / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentAntidepressant Drug Adverse Reaction / Depression1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
  • Labopharm inc
  • Apothecon inc div bristol myers squibb
  • Alvogen inc
  • American therapeutics inc
  • Apotex inc
  • Matrix laboratories ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apothecon
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Barr Pharmaceuticals
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • DispenseXpress Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Labopharm Inc.
  • Lake Erie Medical and Surgical Supply
  • Letco Medical Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Neighborcare Repackaging Inc.
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharma Pac LLC
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Shanghai World Prospect Industrial Co. Ltd.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral150 mg
TabletOral50 mg
TabletOral300 mg
Tablet, extended releaseOral150 mg/1
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral300 mg/1
TabletOral100 mg
TabletOral75 mg
Kit
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral300 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral50 mg/1
TabletOral68.25 mg
Prices
Unit descriptionCostUnit
Trazodone hcl powder8.26USD g
Desyrel 300 mg tablet6.03USD tablet
TraZODone HCl 300 mg tablet5.65USD tablet
Trazodone 300 mg tablet5.44USD tablet
Desyrel 100 mg tablet4.6USD tablet
Desyrel 150 mg tablet3.39USD tablet
TraZODone HCl 150 mg tablet1.53USD tablet
Trazodone 150 mg tablet1.47USD tablet
Desyrel 50 mg tablet1.33USD tablet
TraZODone HCl 100 mg tablet0.76USD tablet
Trazodone 100 mg tablet0.73USD tablet
Apo-Trazodone D 150 mg Tablet0.61USD tablet
Desyrel Dividose 150 mg Tablet0.61USD tablet
Novo-Trazodone 150 mg Tablet0.61USD tablet
Nu-Trazodone-D 150 mg Tablet0.61USD tablet
Ratio-Trazodone 150 mg Tablet0.61USD tablet
TraZODone HCl 50 mg tablet0.59USD tablet
Trazodone 50 mg tablet0.57USD tablet
Nu-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 100 mg Tablet0.41USD tablet
Ratio-Trazodone 100 mg Tablet0.41USD tablet
Apo-Trazodone 100 mg Tablet0.41USD tablet
Desyrel 100 mg Tablet0.41USD tablet
Mylan-Trazodone 100 mg Tablet0.41USD tablet
Novo-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 75 mg Tablet0.34USD tablet
Apo-Trazodone 50 mg Tablet0.23USD tablet
Mylan-Trazodone 50 mg Tablet0.23USD tablet
Novo-Trazodone 50 mg Tablet0.23USD tablet
Nu-Trazodone 50 mg Tablet0.23USD tablet
Pms-Trazodone 50 mg Tablet0.23USD tablet
Ratio-Trazodone 50 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8133893No2009-03-132029-03-13Us
US6607748No2000-06-292020-06-29Us
US7829120No2007-03-272027-03-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)87 °CPhysProp
water solubilitySparigly solubleNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.29 mg/mLALOGPS
logP2.68ALOGPS
logP3.13ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.39 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity105.88 m3·mol-1ChemAxon
Polarizability40.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9829
Caco-2 permeable-0.6166
P-glycoprotein substrateSubstrate0.547
P-glycoprotein inhibitor IInhibitor0.8634
P-glycoprotein inhibitor IIInhibitor0.8889
Renal organic cation transporterInhibitor0.6479
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6613
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.83
Ames testNon AMES toxic0.5133
CarcinogenicityNon-carcinogens0.8545
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8994
hERG inhibition (predictor II)Inhibitor0.7503
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-7980000000-5d2bde624fdd9a946993
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0609000000-cee74b5bf3182c2aa324

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aryl 1,2,4-triazolones / Triazolopyridines / Aniline and substituted anilines / Dialkylarylamines / Pyridinones / Chlorobenzenes / N-alkylpiperazines / Aryl chlorides / Heteroaromatic compounds
show 7 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aryl 1,2,4-triazol-3-one / Triazolopyridine / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Pyridinone / Chlorobenzene / N-alkylpiperazine
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, monochlorobenzenes, N-alkylpiperazine, triazolopyridine (CHEBI:9654)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Pazzagli M, Giovannini MG, Pepeu G: Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999 Nov 3;383(3):249-57. [PubMed:10594316]
  2. Marcoli M, Rosu C, Bonfanti A, Raiteri M, Maura G: Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther. 2001 Dec;299(3):1106-11. [PubMed:11714900]
  3. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657]
  4. Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G: A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1117-27. [PubMed:15610924]
  5. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120]
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl). 1995 May;119(2):222-30. [PubMed:7659770]
  2. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Odagaki Y, Toyoshima R, Yamauchi T: Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. [PubMed:15888508]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  3. Subhash MN, Srinivas BN, Vinod KY: Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sci. 2002 Aug 16;71(13):1559-67. [PubMed:12127910]
Details
5. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  3. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194]
  2. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Wen B, Ma L, Rodrigues AD, Zhu M: Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. doi: 10.1124/dmd.107.019471. Epub 2008 Jan 31. [PubMed:18238857]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2018 20:22